Mario Lacouture, MD
Dr. Mario E. Lacouture is a Professor of Dermatology at Weill Cornell Medicine and a Member Attending at Memorial Sloan Kettering Cancer Center. Dr. Lacouture received his medical degree from Javeriana University in Bogota, Colombia and completed an internship in General Surgery at The Cleveland Clinic. He then went on to complete his residency in dermatology at The University of Chicago, Illinois and postdoctoral work at Brigham and Women’s Hospital in Boston.
Dr. Lacouture has a special interest in dermatologic conditions in cancer patients and survivors that result from cancer treatments, such as chemotherapy, radiotherapy, and/or immunotherapies. He is a well-known lecturer in the United States and abroad on caring for conditions affecting the skin, hair, and nails in those living with cancer. In addition, Dr Lacouture conducts clinical trials to discover ways to treat dermatologic side effects during treatment, such as ways to prevent hair loss, itching, dry skin, and nail changes during and after treatment.
Dr. Lacouture is currently the Founder and Vice-Chair of the Skin Toxicity Study Group of the Multinational Association of Supportive Care in Cancer and is on the advisory board of various patient-based support organizations. In 2012, CancerCare named Dr. Lacouture Physician of the Year for his contributions to the education of people living with cancer, and has been on Castle-Connolly and New York Magazine’s list of Top Doctors (2014-2018). Dr Lacouture has published over 230 articles in peer-reviewed journals and is the author of the patient-directed book “Dr. Lacouture’s Skin Care Guide for People Living With Cancer” and the textbook for healthcare providers “Dermatologic Principles and Practice in Oncology”.
In the past two years, Dr. Lacouture has served as a consultant/advisor and/or speaker for Legacy Healthcare Services, Adgero Bio Pharmaceuticals , Amryt Pharmaceuticals, Celldex Therapeutics, Debiopharm, Galderma Research and Development, Johnson and Johnson, Novocure Inc, Lindi, Merck Sharp and Dohme Corporation, Helsinn Healthcare SA, Janssen Research & Development LLC, Menlo Therapeutics, Novartis Pharmaceuticals Corporation, F. Hoffmann-La Roche AG, AbbVie Inc, Boehringer Ingelheim Pharma Gmbh & Co. KG, Allergan Inc, Amgen Inc, E.R. Squibb & Sons LLC, EMD Serono Inc, Astrazeneca Pharmaceuticals LP, Genentech Inc, Leo Pharma Inc, Seattle Genetics, Bayer, Manner SAS, Lutris, Pierre Fabre, Paxman Coolers, Adjucare, Dignitana, Biotechspert, Teva Mexico, Parexel, OnQuality Pharmaceuticals Ltd, Novartis, Harborside, Wiley, Azitra, NCODA and Takeda Millenium.